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Abstract: Single stranded microbial DNA fragments with unmethylated deoxycytidylyl-deoxyguanosine 
dinucleotide (CpG) motifs are interpreted as danger signals by the innate immune system via recognition on 
Toll-like Receptor 9 (TLR9). Their synthetic analogues, Oligodeoxynucleotides (ODN) comprise a promising 
class of immune modulators with potential applications in the treatment of multiple diseases, such as cancer, 
autoimmune diseases or allergy. ODN molecules contain a core hexamer sequence, which is species specific consisting of 
GACGTT and AACGT for mouse and GTCGTT in humans. Asses ment of  structural features  of different type of ODNs 
is highly challenging. NMR spectroscopic insights were gained for a short, single CpG motif containing ODN 1668. The 
structural basis of ODN recognition by TLR9 recently started to unravel as crystal structures of TLR9 orthologues in 
complex with ODN 1668 were solved. Systematic investigations of ODN sequences revealed that ODNs with a single CpG 
motif are capable of activating mouse TLR9, but twoclosely positioned CpG motifs are necessary for activ tion of human 
TLR9. Furthermore, longer ODNs with TCC and TCG sequences at the 5’ end were shown to activate TLR9 with higher 
efficiency. It was revealed that 5’-xCx motif contai ing short ODNs (sODN) are able to augment the immune response of 
short, single CpG containing ODNs, which are incapable of activating of TLR9 alone. All these observations pointed to the 
existence of a second binding site on TLR9, which was characterized in crystal structures that delivered further insights of 
the nucleic acid recognition of the innate immune system by TLR9.  
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1. INTRODUCTION 
 The modulation of the immune system activity is a 
required pharmacological intervention for many medical 
conditions bearing particular importance in the treatment of 
inflammatory diseases, autoimmune diseases, in transpl t 
procedures, infectious diseases and in developing new 
vaccines against infections and cancer [1]. Mechanisms 
leading to immunomodulation may involve either the innate 
or the adaptive immune system, the underlying molecular 
players are, however, distinctly different. The innate immune 
system recognizes microbes [2] by means of Pattern 
Recognition Receptors (PRR), which are conserved in 
evolution to bind unique molecular signatures of microbial 
metabolism not produced by the host organism. These ighly 
conserved structural motifs are known as Pathogen-
Associated Molecular Patterns (PAMP) and are used as 
templates for the development of novel therapeutic immune 
modulators.  
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 Among PAMPs of microbial origin, CpG motif containing 
bacterial or viral single stranded DNA (ssDNA) fragments are 
recognized as unique microbial danger signals by TLR9 [3]], 
which belongs to an important family of PRRs of theinnate 
immunity. TLRs [4] are critical for effective host defenses 
against numerous pathogens being able to link innate 
immunity to adaptive immunity. TLR9 [5] belongs to he 
subgroup of TLRs, which sense nucleic acids and is localized 
intracellularly in the endosomal compartment. It is expressed 
in B cells, plasmacytoid dendritic cells (pDC) and monocyte-
macrophage-lineage cells in humans [6] and in macrophages 
and bone marrow-derived dendritic cells in mouse [7]. 
Activation of TLR9 triggers the MyD88-dependent signaling 
cascade that induces transcription factors (NF-κβ, AP1, IRF7) 
in the nucleus initiating the production of inflammatory 
cytokines and chemokines. TLR9 activation leads to Th1 
dominated immune responses, inducing B-cell-proliferation, 
maturation of pDCs and the secretion of cytokines [8]. 
 Since ssDNA fragments in the endosomes are a results of 
degradation of large double stranded DNA (dsDNA) of 
bacterial or viral origin, activation of immune responses also 
requires processing [9] of larger microbial dsDNA as well as 
cellular and endosomal uptake [10] [11]. 
 Synthetic analogues of bacterial and viral DNA, CpG 
ODNs are important immune modulators and represent the 
most advanced potential adjuvants [12]. CpG ODNs are able 
to activate the innate immunity by binding to TLR9 and 
trigger Th1-dominated immune responses. Chemically, CpG 
ODNs are synthetic ssDNA sequences with unmethylated 
CpG-motifs. When used as vaccine adjuvants, they improve 
the function of professional antigen-presenting cells and boost 
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immune responses [5]. Due to their Th1 response induci g 
ability, CpG ODNs are in clinical testing as adjuvants in 
cancer immunotherapy [13] [14]. 
 Conformational properties and determinants of receptor 
recognition are important in understanding the structural 
requirements for receptor activation and inhibition, for 
cellular and endosomal uptake and for formulation of delivery 
systems for CpG ODN adjuvants in vaccines, thus, in ge eral 
for improving the therapeutic use of CpG ODNs. In this mini-
review, an overview of studies investigating the sequences, 
structural features and the molecular determinants of receptor 
recognition of CpG ODNs will be given.  
 
1.1. CpG ODN sequences and structure activity 
relationships 
The immune stimulatory properties of CpG ODNs is 
dependent on the length of the sequence, the number of CpG 
motifs and the residues flanking the CpG motif, the distance 
between the motifs and the resulting structural properties [15]. 
In addition sequence selectivity of TLR9 recognition is also 
species specific.  
The specific sequence motif recognized by TLR9 consists 
of an unmethylated CpG dinucleotide flanked by two 5’ 
purines and two 3’ pyrimidines with the general formula of 
RRCGYY, where R is a purine containing nucleotide and Y 
is pyrimidine based. In mice, the core hexamer is GACGTT 
and AACGT, while in humans GTCGTT is the optimal 
minimal immune stimulatory sequence [16]. 
There are three main classes and one subclass of CpG 
ODNs described in primates as shown in Figure 1 [17].  
A type CpG ODNs (former D type) contain a single 
hexameric purine / pyrimidine / CG / purine / pyrimidine 
motif flanked by self-complementary bases capped at the 3’ 
end by a poly G tail [18] as shown in Figure 1. A type CpG 
ODNs are poor stimulators of B cells and only modestly 
induce pDC maturation inducing secretion of type I IFNs 
(IFN-α/β), TNF-α, IL-12, and IFN-γ–IP10 [19-23]. 
B type CpG ODNs (former K type) contain multiple 
isolated CpG motifs (depicted in Figure 1) with 
phosphorothiolate bond in place of the phosphodiester 
linkage. The phosphorothiolate bond decreases the 
susceptibility to DNase digestion and improves uptake 
resulting in longer in vivo half-life/bioavailability than 
phosphodiester bond containing ODNs, however, it was 
reported recently that the phosphodiester bond is strongly 
favored by TLR9 [24]. B type CpG ODNs are the most 
stimulatory among the classes with being poor inducers of 
IFN-α with the ability to induce robust maturation of pDC and 
strong B-cell proliferation [3, 25]. 
C type ODNs contain a TCGTCG sequence at the 5’ end 
and include a CG-rich palindrome (shown in Figure 1). C type 
CpG ODNs combine the immune stimulatory properties of A
and B type ODNs [26-28] by being able to directly simulating 
B cells to secrete IL-6 and pDCs to produce IFN-α. 
P-class CpG ODNs were developed from C type CpG 
ODNs [29] and are a variation of thereof. They contain two 
palindromes as depicted in Figure 1 and induce effici nt INF-
α responses. 
 
Figure 1 The sequences of different types of ODNs. Self-
complementary palindromic sequences are depicted different 
shades of the same color and underlining, while the
nucleotides of the CpG motifs are denoted in white letters. 
 
Recent systematic analysis of B and C type CpG ODNs for 
human TLR9 have shown that the minimal sequence motif 
required for the activation of human [15] and mouse TLR9 are 
different [15]: one CpG motif localized close (4-6 nucleotide) 
to the 5’ end is sufficient for the activation of mouse TLR9, 
while two, closely positioned (6-10 nucleotide distance) CpG 
motifs are necessary for human TLR9.  
Furthermore, it has been determined that, in addition to the 
CpG motif, a TCG or TCC sequence at the 5' end of the 
molecule and length of 20-30 nucleotides more effici ntly 
activate TLR9 [15, 30]. This indicated that nucleotides at the 
5’ end are also important and also suggested an additional 
binding site apart from the site for the CpG motif (see more 
details in 1.3.2). Specifically, mouse TLR9 activaton [30] is 
augmented by a 5’TCC sequence one to three nucleotides 
from the CG present. Based on this result, they proposed a 23-
mer CpG ODN, called minM80, with the sequence 5’-
TCCT3CGT15. For efficient human TLR9 activation [15] the 
first CpG motif is preceded by the 5’-thymidine and the 
elongated poly-thymidine tail at the 3’ end. Based on these 
findings they proposed a human specific agonist, minH75, a 
24-mer with the sequence of sequence of 5’-TCGT7CGT12. 
Furthermore, short ssDNA sequences with a 5’ TCG motif 
(sODN), while unable of activate TLR9 themselves, were 
found to augment the TLR9 activation both in mouse and 
human cells lines [31-32]. Also, while single CpG motif 
containing ODNs are incapable of human TLR9 activation 
alone [15], together with sODNs they are able to bypass the 
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1.2. Structural features of CpG ODNs in solution 
 While much of attention has been focused on the solution 
structure of dsDNA, ssDNA is less well characterized. The 
physical basis of structure formation of ssDNA is dr ven by base 
pairing between complementary nucleotides, while stacking 
interaction between adjacent bases and electrostatic interactions 
also play a crucial role [33] [34]. As a result, ssDNA structure is 
varied involving local secondary structure elements interspaced 
with random coil conformations, and it is also affected by 
solution state conditions (salt, pH, temperature, GC content, 
sequence). Self-complementary palindrome sequences enable 
intra- or intermolecular interactions via base pairing. The base 
pairing could involve canonical Watson-Crick or alternative 
Hoogsteen bonds. Oligomer formation could be a result of 
intermolecular base pairing interactions. 
Figure 2 Schematic depiction of possible structural 
arrangements of different type of ODNs based on base p iring 
between complementary palindrome sequences. 
 Structural aspects, such as oligomerization of CpG ODNs 
has been shown to modulate their activities [29]. Structural 
propensities of CpG ODNs can be inferred from the presence 
of self-complementary palindrome sequences. Possible 
secondary structures could be predicted based on favorable 
canonical base pairing in the sequences as implement d in the 
mfold [35] program, Structures observed experimentally for 
different type of CpG ODNs are summarized in Figure 2. 
A type CpG ODNs contain palindrome capable of forming a 
stem-loop structure (shown in Figure 2) capped at the 3’ end 
by a poly G tail. The latter is suspected to form G 
tetrads/quadruplexes via Hoogsteen base pairs and form  
nanoparticles [36] in endolysosomes or to convert to short 
linear B type segments upon degradation by DNase II [9]. This 
latter hypothesis, however, makes it difficult to explain 
differing activities of A and B type CpG ODNs, unless uptake 
is enhanced by nanoparticle formation. 
 B type CpG ODNs were assumed to occur mostly in 
extended, random coil conformation [29], however, later a 
dimerization interface of ODN 1668 as depicted in Figure 2 
was shown by NMR [37] [38] (see below). Formation of 
dimer structures were observed at low temperature (283K), in 
solutions with 10 mM phosphate buffer at pH 7. It is, however, 
debated if they are also formed under physiological conditions 
(at 37oC) and it is widely accepted that B type ODNs are 
extended short linear ssDNAs. 
 C type CpG ODN also contain a palindrome [26, 39-40], 
which may form either an intramolecular stem-loop structure 
in monomeric conformation or a serves as a dimerization 
interface as show in Figure 2.  
P type ODNs contain a double palindrome, which can 
resolve into monomeric structures with a double hairpin-like 
conformation, a dimer containing a single hairpin  or 
multimeric structures [29] as depicted in Figure 2. 
 Structural features have only been investigated in the case 
of B type CpG ODN 1668 and its fragments (shown in Figure 
3) using NMR spectroscopy[37] [38]. The high resoluti n 
structure of the core hexamer, 1, of B type CpG ODN 1668 
(Figure 3) was determined by NMR [38] and found to form a 
dimer double helix. A decamer with 2-2 residues flanking the 
core hexamer, 2, the tetradecamer, 3 the eicosamer full ODN 
1668, 4, and the pentaeicosamer, 5 also showed signs of 
partial duplex formation in 10mM phosphate buffered, pH 7, 
150 mM NaCl solution [38]. The concentrations of the 
samples were between 2-5 mM and spectra were measured 
283K. These conditions do not represent physiological 
conditions, where ODN concentrations are lower and 
temperature is higher, however, these conditions could be 
relevant for in vitro immobilization of ODN immune 
modulators in drug delivery formations. The duplex formation 
was attributed to intermolecular base pairing via hydrogen 
bonds at the core hexamer, while the terminals were likely 
folded back onto the core region forming non-canonical 
structures.  
Figure 3 Fragments of CpG ODN 1668 studied by NMR.  
 
1.3. Receptor bound CpG ODN conformations 
 The structural determinants of CpG ODN binding by 
TLR9 were revealed by crystal structures [41] that were 
obtained for several orthologues of TLR9 in a liganded and 
unliganded states together with a short B type CpG ODN 
1668. The picture was further refined after a second bi ding 
site has been suggested for ssDNA in human TLR9 [15] [3 ], 
structures with occupying the second site of human TLR9 by 
sODN or by a longer immune stimulatory CpG ODN with two 
CpG motifs has been solved [32]. Later structural information 
on mouse TLR9 activation was also provided [42]. 
 
 
1.3.1. TLR9  
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 Structurally TLR9, like all TLRs, is a single 
transmembrane protein, which consists of an N terminal 
ligand-binding comprised of Leucine Rich Repeats (LRR), a 
single membrane spanning domain and a C terminal s gnaling 
Toll/1L-1R Homology (TIR) domain. The LRR domain tha  
recognizes PAMPs, which leads to oligomerization and 
activation of signaling mediated by the TIR domain.  
 
1.3.2. Structures of TLR9 with agonistic CpG ODN and 
inhibitory DNA  
 The crystal structure of the unliganded C terminal domain 
of mouse TLR9 has been solved [43], however, reveald little 
regarding the molecular determinants of CpG motif 
containing ssDNA binding. 
Figure 4 Shape and arrangement of LLR domain of TLR9 a) 
unliganded, b) with agonistic CpG ODN and c) inhibitory 
DNA.  
 The structural basis of CpG ODN recognition by TLR9 
has first been revealed by crystallographic structures on 
complexes between TLR9 orthologues and a short, B type
CpG ODN with a single CG motif [41]. The crystal structures 
solved also show structural determinants for molecular 
recognition of inhibitory ssDNA. Crystal structures of 
orthologues from equine (Equus caballus), from bovine (Bos 
Taurus), and murine (Mus musculus) were investigated. 
Unliganded equine (3WPB) and murine (3WPF) forms of 
TLR9 were found to be monomeric as well as equine (3WPD) 
and murine (3WPG, 3WPH, 3WPI) TLR9 complexes with 
inhibitory ssDNA as opposed to agonistic ssDNA bound 
equine (3WPC) TLR9, which was shown to be dimeric. The 
arrangements are summarized in Figure 4.  
 Agonistic ssDNA, B-type ODN 1668 depicted in Figure 
4b, acts as a molecular glue between the LLR domains of two 
TLR9 receptors leading to the formation of a TLR9 dimer that 
in turn initiates the signaling cascade leading to the activation 
of proinflammatory agents. The agonistic DNA bound TLR9 
have an "m"-shaped 2:2 complex, whereby the C termini of 
the TLR9 protomers are positioned in the center. The 
agonistic ssDNA binds with its 3' end to the N terminal LLR0-
11 of one TLR9 and the 5' part binds to the C terminal LLR20-
22 of the other TLR9.  
 It has been shown that only disordered CpG containi g 
ssDNA can act as an agonist, CpG motif containing ssDNA 
with secondary structure binds with much lower affinity to 
TLR9 LRRs. This highlights the importance of interactions 
formed by the bases of the ssDNA, which are buried in the 
interior of DNA forming duplexes. Indeed, in the crystal 
structure of agonistic ssDNA, interface-1 (Figure 5a) 
recognizes the bases of the CpG motifs, interactions at 
interface-2 primarily involves interactions with the backbone 
of the CpG ssDNA. 
Figure 5 Schematic representations of crystallographic 
structures of TLR9 complexes with a) two agonistic CpG 
ODN (1668) with two TLR9 molecules (first TLR9 in green, 
second TLR9 in braun) at interfaces-1 and -2, b) short, 10-
mer, CpG ODN and a short (6-mer) ssDNA with 5’ xCx motif, 
c) short CpG ODN with a 5’ xCx motif and c) longer CpG 
ODN with a 5’ xCx motif. 
 The bases of the nucleotides are involved in direct and 
water mediated hydrogen bonds to amino acids of interface-1 
consisting of LRRNT-1-2 of the N terminal part of the first 
TLR9 molecule. Stacking interactions were found between 
the nucleotide bases and aromatic amino acids such as Phe or 
Trp. Backbone phosphate groups of ssDNA interact with 
positively charged Lys, Arg and His sidechains. Interactions 
of the N2 atom in guanine in the CpG motif appears to be 
defining specificity of the CpG ODN towards the LRR 
domain of TLR9.  At interface-2 containing LLR-20-22 from 
the C-terminal fragment of the second TLR9, there a
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hydrogen bonds towards phosphate groups and van der Waals 
interactions to the sugar moieties of the ssDNA.  
 Complexes of TLR9 with inhibitory DNA were obtained 
and found to be monomeric as depicted in Figure 4c. The 
inhibitory ssDNA formed stem-loop structures by 
intramolecular base pairing that fit snugly into the interior ring 
of the LLR domain of TLR9. The stem-loop structure is 
formed by intramolecular base pairing between 
complementary 3-4 bases, which may also contain a 
mismatched pair and a short (3 bases) or a long (8 bases) loop. 
The recognition is driven by interactions involving the 
backbone of the inhibitory ssDNA, but also required contacts 
to the base of a non-base paired guanidine at the 3' end. 
Antagonistic effect of inhibitory ssDNA to disordered CpG 
ssDNA arises due to the fact that their binding sites overlap. 
 
1.3.2. Structural determinants of the second ssDNA binding 
site of TLR9 
It was shown that human TLR9 requires at least two CG 
motifs separated by 6-10 nucleotides for activation [15]. 
These double CpG ODNs are called immune stimulatory 
ODNs [31-32]. However, sODNs, which specifically augment 
TLR9 response with double CpG ODNs, can bypass the 
requirement of two CpG motifs in human TLR9 [31-32]. In 
same study it was shown that longer CpG ODN sequences 
with a TCG or a TCC motif at the 5’ end were shown to 
activate TLR9 more efficiently than shorter CpG ODN 
without such motif at the 5’ end [15]. All these findings 
suggested the existence of second ssDNA binding site on LLR 
domain of TLR9.  
Model building of human TLR9 based on the crystal 
structures of orthologous TLR9 combined with a mutagenesis 
study [31] have been used to localize the residues important 
for the putative second binding site. Various biochemical 
biophysical and cell biological investigations [42] have shown 
that binding to the second site cooperatively promote receptor 
dimerization and activation. Investigations of the sequence 
requirements for the second binding site have shown that an 
ssDNA containing cytosine at the second position frm the 5'-
end is needed and thus was called a 5'-xCx motif.  Finally, 
crystallographic structures of equine (Equus caballus) 5Y3J, 
5Y3K, 5Y3L and bovine (Bos Taurus) 5Y3M TLR9 
orthologues in complex with various CpG ssDNA pinpoi ted 
the exact place and binding mode of the second binding site 
as summarized in Figure 5b, c and d.  
Using two ssDNA sequence, one with a short (10-mer) CpG 
ODN and an even shorter 6-mer with 5'-xCx motif, the former 
assumed the same binding mode as has been found previously 
[41], while the latter bound to the newly identified binding site 
in the middle of the LLR domain at LRR17-19 on one TLR9 
molecule and LRR11 on the other TLR9. Indeed, only the last 
three 3’ residues made contact with the ligand binding 
domains of the two TLR9, T1 and C2 connecting to both while 
G3 bound to only one TLR9 as shown in Figure 5b. These 
short 5'-xCx motif containing ssDNA sequences cannot 
activate TLR9 alone, and bind to the second site only when 
the first one is occupied.  
 CpG ODNs containing both CpG and 5'-xCx motifs are
strong activators of TLR9. These so called immune 
stimulatory CpG ODNs [44] and showed two alternative ypes 
of binding modes. The short sequence (Figure 5c) was un ble 
span both binding sites, thus bound to both individually, while 
the long sequence (Figure 5d) was able to stretch out to cover 
both binding sites. 
 Thus it has been shown that human TLR9 contains two 
binding site, a primary CpG motif site and a secondary site for 
the 5’ xCx motif, which acts synergistically to induce TLR9 
activity. 
 Finally, structural features of mouse TLR9 activation were 
clarified [42]. A single CpG motif containing ODN is 
sufficient for efficient activation, however, dimerization of 
mouse TLR9 can also be further enhanced by 5’-xCx ssDNA 
as with human TLR9. The latter effect was also observed for 
equine TLR9. No crystal structures could be obtained for 
mouse TLR9 and CpG ODN alone, only in addition of a 
sODN. Crystal structure of mouse TLR9 in complex with 10-
mer CpG DNA (AGGCGTTTTT) and 6-mer 5'-xCx DNA 
(TCGCCA) was solved (5ZLN), in which both ligands bound 
to their corresponding binding sites with similar 
conformations as observed with equine complex (5J3J). Most 
residues contributing to CpG ODN binding were conserved in 
mouse and equine TLR9 complexes with the exception of 4 
amino acids. Furthermore, some differences in the residues 
contributing to the protein-protein interactions atthe 
dimerization interaction were found. It was found with Size 
Exclusion Chromatography analysis that the mouse TLR9 
dimer complex with CpG ODN alone and with CpG ODN and 
sODN combination are more similar to each other than 
analogous equine structures. It was concluded that in spite of 
overall similarity, the murine TLR9 is more easily dimerizes 
than the equine orthologue due to species specific dif erences 
in their sequences.  
 
CONCLUSION 
 Selectivity between pathogenic microbial and endogen us 
DNA sequences of the host is based on multiple factors. CpG 
motifs are more frequent in prokaryotic than in eukaryotic 
genome, furthermore, in the latter cysteine residues ar  often 
methylated [45]. Compartmentalization of TLR9 in the 
endosome and its acidic environment with nuclease activity 
also contributes to the selectivity between pathogenic and 
endogenous DNA fragments[46]. Endogenous DNA from 
apoptotic cells is also protected by histones from DNases. The 
requirement for binding to the second binding site in human 
TLR9 was proposed to contribute to further selectivity [44].  
 Crystal structures of TLR9 in complex with a short CpG 
ODN have shown that recognition of DNA by TLR9 receptors 
requires unstructured regions of ssDNA for binding, while 
inhibitory ssDNA with structured, duplex regions prevents 
oligomerization of TLR9 and thus inhibits dimerizaton and 
subsequent activation of immune stimulatory signaling.  
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The structural features of unbound CpG ODNs free in 
solution are less clear than that of the ODNs in the bound form. 
While an NMR study has found intermolecular dimer formation 
for B type CpG ODN 1668 in vitro, studies under physiological 
conditions indicate disordered monomers. Conformation l 
studies of A and C type CpG ODNs, however, have shown 
formation of secondary structure elements either by intra- or 
intermolecular interactions.  
If such structured states of CpG ODNs exist in solution, they 
have to unfold or shift equilibrium between folded and unfolded 
states towards disordered binding-competent conformation to 
bind the receptor as depicted in Figure 6. The unfoldi g event is 
associated with an entropic penalty, which needs to be 
compensated by enthalpic contributions to the binding coming 
from favorable interactions with the receptor. If the binding-
competent disordered conformation is dominant in the 
conformational ensemble, the binding is entropically f vored in 
accordance with the principle of conformational selection. 
Similar reasoning is valid for inhibitory ssDNA, whic  binds 
TLR9 in a duplex containing a stem-loop form.  
Although, it is worth noting, that the equilibrium could also 
be shifted upon digestion of duplex containing state  by DNases 
[9]. It has been shown that immune response to A type CpG 
ODNs is impaired without the presence of DNase II enzymes in 
endolysosomes, which was observed to digest 20-mer A type 
CpG ODNs molecules into 11-12-mers containing the 3’ nd 
including the CG motif. These fragments resemble linear 
fragments of B type CpG DNA, which do not show the same 
dependence on DNase digestion. As a possible explanation the 
authors reason that duplex regions of A type CpG ODNs prevent 
recognition of the CG motif. 
Figure 6 Conformational selection of CpG ODNs for binding 
TLR9  
 By conformational selection, the thermodynamic character 
influencing binding strength is dependent on the conformational 
ensemble of CpG ODNs. Further insights in the structu al 
properties of CpG ODNs affecting the energetics of the binding 
could be exploited for the design of CpG ODN sequences that are 
better activators of TLR9, or more suited for surface dsorption 
on carriers of delivery systems or more efficiently taken up. 
Conformational studies of ssDNA are, however, highly 
challenging due their intrinsic flexibility. As described above, 
some attempts were made to investigate the structural 
propensities of CpG ODNs in the years following discovery of 
their immune stimulatory properties, but comprehensiv  
understanding of their conformations is still missing.  
 Crystal structures provided crucial insight into the 
interactions between ssDNA and TLR9, however, they represent 
static snapshots without information on dynamics of the 
complex. Indeed, it has been proposed that the stability of equine 
and murine TLR9 complexes with the same ligands are distinctly 
different. Biomolecular simulations applied to the complex 
structure could provide detailed insights into the dynamic 
processes underlying these observations. 
 From a structural point of view, the case of unstructured 
ssDNA versus dsDNA is similar to the case of Intrinsically 
Disordered Proteins (IDPs) versus structured proteins: 
description of conformational properties is complex and few 
methods are suitable under physiologically relevant co ditions. 
NMR spectroscopy would be a suitable methods to chara terize 
conformational ensembles, however, NMR studies are hindered 
by the size of the ssDNA fragments in samples containi g natural 
abundance NMR active isotopes and by the complexity of 
methods for stable isotope labelling. Again, biomolecu ar 
simulations may provide alternative means to gain insights into 
the conformational properties immune modulatory ssDNA [47]. 
With improvement of computational capacities and the 
development of enhanced sampling algorithms and multiscale 
models, biomolecular simulations may provide a more 
comprehensive description of structural and dynamic features of 
CpG ODNs.   
 
CONFLICT OF INTEREST 
 No conflict of interest. 
 
ACKNOWLEDGEMENTS 
 K.F. acknowledges the support of the Marie Curie Career 
Integration Grant (303917 PGN-INNATE), the Research 
Grant from the Research Foundation-Flanders (1508414N and 
1525517N), János Bolyai Research Scholarship of the 
Hungarian Academy of Sciences (BO/004333/18/7) and the 
New National Excellence Program of Debrecen Universty 




[1] Bartneck, M. Immunomodulatory Nanomedicine. 
Macromol. Biosci. 2017, 17 (10), 13. 
[2] Medzhitov, R.; Janeway, C. A. An ancient system of host 
defense. Current Opinion in Immunology 1998, 10 (1), 12-15. 
[3] Krieg, A. M.; Yi, A. K.; Matson, S.; Waldschmidt, T. J.; 
Bishop, G. A.; Teasdale, R.; Koretzky, G. A.; Klinman, D. M. 
CPG MOTIFS IN BACTERIAL-DNA TRIGGER DIRECT 
B-CELL ACTIVATION. Nature 1995, 374 (6522), 546-549. 
[4] Medzhitov, R. Toll-like receptors and innate immunity. 
Nature Reviews Immunology 2001, 1 (2), 135-145. 
Short Running Title of the Article Journal Name, 2015, Vol. 0, No. 0    7 
[5] Kumagai, Y.; Takeuchi, O.; Akira, S. TLR9 as a key 
receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 
2008, 60 (7), 795-804. 
[6] Hornung, V.; Rothenfusser, S.; Britsch, S.; Krug, A.; 
Jahrsdorfer, B.; Giese, T.; Endres, S.; Hartmann, G. 
Quantitative expression of Toll-like receptor 1-10 mRNA in 
cellular subsets of human peripheral blood mononuclear cells 
and sensitivity to CpG oligodeoxynucleotides. J. Immunol. 
2002, 168 (9), 4531-4537. 
[7] Hemmi, H.; Takeuchi, O.; Kawai, T.; Kaisho, T.; Sato, S.; 
Sanjo, H.; Matsumoto, M.; Hoshino, K.; Wagner, H.; Takeda, 
K.; Akira, S. A Toll-like receptor recognizes bacterial DNA. 
Nature 2000, 408 (6813), 740-745. 
[8] Klinman, D. M. Immunotherapeutic uses of CpG 
oligodeoxynucleotides. Nat. Rev. Immunol. 2004, 4 (4), 248-
257. 
[9] Chan, M. P.; Onji, M.; Fukui, R.; Kawane, K.; Shibata, T.; 
Saitoh, S.; Ohto, U.; Shimizu, T.; Barber, G. N.; Miyake, K. 
DNase II-dependent DNA digestion is required for DNA 
sensing by TLR9. Nat. Commun. 2015, 6, 10. 
[10] Hara, T.; Tanegashima, K.; Takahashi, R.; Nuriya, H.; 
Naruse, N.; Tsuji, K.; Shigenaga, A.; Otaka, A. A Novel 
Function of a CXC-Type Chemokine CXCL14 As a Specific 
Carrier of CpG DNA into Dendritic Cells for Activating Toll-
like Receptor 9-Mediated Adaptive Immunity. Blood 2016, 
128 (22), 5. 
[11] Tanegashima, K.; Takahashi, R.; Nuriya, H.; Iwase, R.; 
Naruse, N.; Tsuji, K.; Shigenaga, A.; Otaka, A.; Hara, T. 
CXCL14 Acts as a Specific Carrier of CpG DNA into 
Dendritic Cells and Activates Toll-like Receptor 9-mediated 
Adaptive Immunity. EBioMedicine 2017, 24, 247-256. 
[12] Montomoli, E.; Piccirella, S.; Khadang, B.; Mennitto, E.; 
Camerini, R.; De Rosa, A. Current adjuvants and new 
perspectives in vaccine formulation. Expert Rev. Vaccines 
2011, 10 (7), 1053-1061. 
[13] Shirota, H.; Tross, D.; Klinman, D. M. CpG 
Oligonucleotides as Cancer Vaccine Adjuvants. Vaccines 
2015, 3 (2), 390-407. 
[14] Scheiermann, J.; Klinman, D. M. Clinical evalution of 
CpG oligonucleotides as adjuvants for vaccines targetin  
infectious diseases and cancer. Vaccine 2014, 32 (48), 6377-
6389. 
[15] Pohar, J.; Krajnik, A. K.; Jerala, R.; Bencina, M. Minimal 
Sequence Requirements for Oligodeoxyribonucleotides 
Activating Human TLR9. J. Immunol. 2015, 194 (8), 3901-
3908. 
[16] Heeg, K.; Dalpke, A.; Peter, M.; Zimmermann, S. 
Structural requirements for uptake and recognition of CpG 
oligonucleotides. Int. J. Med. Microbiol. 2008, 298 (1-2), 33-
38. 
[17] Klinman, D. M. Use of CpG oligodeoxynucleotides as 
immunoprotective agents. Expert Opin. Biol. Ther. 2004, 4 
(6), 937-946. 
[18] Krug, A.; Rothenfusser, S.; Hornung, V.; Jahrsdorfer, B.; 
Blackwell, S.; Ballas, Z. K.; Endres, S.; Krieg, A. M.; 
Hartmann, G. Identification of CpG oligonucleotide 
sequences with high induction of IFN-alpha/beta in 
plasmacytoid dendritic cells. European Journal of 
Immunology 2001, 31 (7), 2154-2163. 
[19] Hartmann, G.; Krieg, A. M. Mechanism and function of 
a newly identified CpG DNA moth in human primary B cells. 
J. Immunol. 2000, 164 (2), 944-952. 
[20] Vollmer, J.; Jurk, M.; Samulowitz, U.; Lipford, G.; 
Forsbach, A.; Wullner, M.; Tluk, S.; Hartmann, H.; Kritzler, 
A.; Muller, C.; Schetter, C.; Krieg, A. M. CpG 
oligodeoxynucleotides stimulate IFN-gamma-inducible 
protein-10 production in human B cells. Journal of Endotoxin 
Research 2004, 10 (6), 431-438. 
[21] Guiducci, C.; Ott, G.; Chan, J. H.; Damon, E.; Calacsan, 
C.; Matray, T.; Lee, K. D.; Man, R. L. C.; Barrat, F. J. 
Properties regulating the nature of the plasmacytoid dendritic 
cell response to Toll-like receptor 9 activation. Journal of 
Experimental Medicine 2006, 203 (8), 1999-2008. 
[22] Verthelyi, D.; Ishii, K. J.; Gursel, M.; Takeshita, F.; 
Klinman, D. M. Human peripheral blood cells differentially 
recognize and respond to two distinct CpG motifs. J. 
Immunol. 2001, 166 (4), 2372-2377. 
[23] Gursel, M.; Verthelyi, D.; Gursel, I.; Ishii, K. J.; 
Klinman, D. M. Differential and competitive activation of 
human immune cells by distinct classes of CpG 
oligodeoxynucleotide. Journal of Leukocyte Biology 2002, 71 
(5), 813-820. 
[24] Pohar, J.; Lainscek, D.; Kunsek, A.; Cajnko, M. .; 
Jerala, R.; Bencina, M. Phosphodiester backbone of the CpG 
motif within immunostimulatory oligodeoxynucleotides 
augments activation of Toll-like receptor 9. Sci Rep 2017, 7, 
11. 
[25] Klinman, D. M.; Yi, A. K.; Beaucage, S. L.; Con ver, J.; 
Krieg, A. M. CpG motifs present in bacterial DNA rapidly 
induce lymphocytes to secrete interleukin 6, interleukin 12, 
and interferon gamma. Proceedings of the National Academy 
of Sciences of the United States of America 1996, 93 (7), 2879-
2883. 
[26] Vollmer, J.; Weeratna, R.; Payette, P.; Jurk, M.; Schetter, 
C.; Laucht, M.; Wader, T.; Tluk, S.; Liu, M.; Davis, H. L.; 
Krieg, A. M. Characterization of three CpG 
oligodeoxynucleotide classes with distinct 
immunostimulatory activities. European Journal of 
Immunology 2004, 34 (1), 251-262. 
[27] Abel, K.; Wang, Y. C.; Fritts, L.; Sanchez, E.; Chung, E.; 
Fitzgerald-Bocarsly, P.; Krieg, A. M.; Miller, C. J. 
Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, 
and C induce distinct ctokine gene expression patterns in 
rhesus monkey peripheral blood mononuclear cells and
distinct alpha interferon responses in TLR9-expressing rhesus 
monkey plasmacytoid dendritic cells. Clinical and Diagnostic 
Laboratory Immunology 2005, 12 (5), 606-621. 
[28] Marshall, J. D.; Fearon, K. L.; Higgins, D.; Hessel, E. M.; 
Kanzler, H.; Abbate, C.; Yee, P.; Gregorio, J.; Dela Cruz, T.; 
Lizcano, J. O.; Zolotorev, A.; McClure, H. M.; Brasky, K. M.; 
Murthy, K. K.; Coffman, R. L.; Van Nest, G. Superior activity 
of the type C class of ISS in vitro and in vivo across multiple 
species. DNA and Cell Biology 2005, 24 (2), 63-72. 
[29] Samulowitz, U.; Weber, M.; Weeratna, R.; Uhlmann, E.; 
Noll, B.; Krieg, A. M.; Vollmer, J. A Novel Class of Immune-
8    Journal Name, 2015, Vol. 0, No. 0 Principal Author Last Name  et al. 
Stimulatory CpG Oligodeoxynucleotides Unifies High 
Potency in Type I Interferon Induction with Preferred 
Structural Properties. Oligonucleotides 2010, 20 (2), 93-101. 
[30] Pohar, J.; Lainscek, D.; Fukui, R.; Yamamoto, C.; 
Miyake, K.; Jerala, R.; Bencina, M. Species-Specific M nimal 
Sequence Motif for Oligodeoxyribonucleotides Activang 
Mouse TLR9. J. Immunol. 2015, 195 (9), 4396-4405. 
[31] Pohar, J.; Lainscek, D.; Ivicak-Kocjan, K.; Cajnko, M. 
M.; Jerala, R.; Bencina, M. Short single-stranded DNA 
degradation products augment the activation of Toll-like 
receptor 9. Nat. Commun. 2017, 8, 13. 
[32] Ohto, U.; Ishida, H.; Shibata, T.; Sato, R.; Miyake, K.; 
Shimizu, T. Toll-like Receptor 9 Contains Two DNA Binding 
Sites that Function Cooperatively to Promote Receptor 
Dimerization and Activation. Immunity 2018. 
[33] Martinez, J. M.; Elmroth, S. K. C.; Kloo, L. Influence of 
sodium ions on the dynamics and structure of single-stranded 
DNA oligomers: A molecular dynamics study. J. Am. Chem. 
Soc. 2001, 123 (49), 12279-12289. 
[34] Zhang, Y.; Zhou, H. J.; Ou-Yang, Z. C. Stretching single-
stranded DNA: Interplay of electrostatic, base-pairing, and 
base-pair stacking interactions. Biophys. J. 2001, 81 (2), 
1133-1143. 
[35] Zuker, M. Mfold web server for nucleic acid folding and 
hybridization prediction. Nucleic Acids Res. 2003, 31 (13), 
3406-3415. 
[36] Kerkmann, M.; Costa, L. T.; Richter, C.; Rothenfusser, 
S.; Battiany, J.; Hornung, V.; Johnson, J.; Englert, S.; 
Ketterer, T.; Heckl, W.; Thalhammer, S.; Endres, S.;
Hartmann, G. Spontaneous formation of nucleic acid-based 
nanoparticles is responsible for high interferon-alph  
induction by CpG-A in plasmacytoid dendritic cells. Journal 
of Biological Chemistry 2005, 280 (9), 8086-8093. 
[37] Narayanan, S.; Dalpke, A. H.; Siegmund, K.; Heeg, K.; 
Richert, C. CpG Oligonucleotides with modified termini and 
nicked dumbbell structure show enhanced 
immunostimulatory activity. J. Med. Chem. 2003, 46 (23), 
5031-5044. 
[38] He, G. Y.; Patra, A.; Siegmund, K.; Peter, M.; Heeg, K.; 
Dalpke, A.; Richert, C. Immunostimulatory CpG 
oligonucleotides form defined three-dimensional structures: 
Results from an NMR study. ChemMedChem 2007, 2 (4), 
549-560. 
[39] Hartmann, G.; Battiany, J.; Poeck, H.; Wagner, M.; 
Kerkmann, M.; Lubenow, N.; Rothenfusser, S.; Endres, S. 
Rational design of new CpG oligonucleotides that combine B 
cell activation with high IFN-alpha induction in plasmacytoid 
dendritic cells. European Journal of Immunology 2003, 33 
(6), 1633-1641. 
[40] Marshall, J. D.; Fearon, K.; Abbate, C.; Subramanian, S.; 
Yee, P.; Gregorio, J.; Coffman, R. L.; Van Nest, G.
Identification of a novel CpG DNA class and motif tha  
optimally stimulate B cell and plasmacytoid dendritic cell 
functions. Journal of Leukocyte Biology 2003, 73 (6), 781-
792. 
[41] Ohto, U.; Shibata, T.; Tanji, H.; Ishida, H.; Krayukhina, 
E.; Uchiyama, S.; Miyake, K.; Shimizu, T. Structural b sis of 
CpG and inhibitory DNA recognition by Toll-like recptor 9. 
Nature 2015, 520 (7549), 702-U303. 
[42] Ishida, H.; Ohto, U.; Shibata, T.; Miyake, K.; Shimizu, 
T. Structural basis for species-specific activation of mouse 
Toll-like receptor 9. FEBS letters 2018. 
[43] Collins, B.; Wilson, I. A. Crystal structure of the C-
terminal domain of mouse TLR9. Proteins 82 (10), 2874-
2878. 
[44] Pohar, J.; Yamamoto, C.; Fukui, R.; Cajnko, M..; 
Miyake, K.; Jerala, R.; Bencina, M. Selectivity of Human 
TLR9 for Double CpG Motifs and Implications for the 
Recognition of Genomic DNA. J. Immunol. 2017, 198 (5), 
2093-2104. 
[45] Stacey, K. J.; Young, G. R.; Clark, F.; Sester, D. P.; 
Roberts, T. L.; Naik, S.; Sweet, M. J.; Hume, D. A. The 
molecular basis for the lack of immunostimulatory activity of 
vertebrate DNA. J. Immunol. 2003, 170 (7), 3614-3620. 
[46] Barton, G. M.; Kagan, J. C. A cell biological view of 
Toll-like receptor function: regulation through 
compartmentalization. Nature Reviews Immunology 2009, 9 
(8), 535-542. 
[47] Feher, K. Atomistic simulations of immune stimulatory 
single stranded bacterial DNA. In SQBP Presindet's Meeting 
2018,  Barcelona, Spain, 2018. 
 
 
Received: March 20, 2015 Revised: April 16, 2015       Accepted: April 20, 2015 
 
 
